AstraZeneca announced on Tuesday that the clinical trial of its long-acting antibody cocktail has not provided evidence of effectiveness in protecting people exposed to the coronavirus.
The company said the participants in the trial were unvaccinated adults older than 18 years with confirmed exposure to a person with the coronavirus within the past eight days, the company noted that the antibody cocktail lowered the risk of developing a symptomatic infection by 33%, which is not a statistically significant result.
“While this trial did not meet the primary endpoint against symptomatic illness, we are encouraged by the protection seen in the PCR negative participants following treatment with AZD7442,” Mene Pangalos, AstraZeneca executive vice president, said in a statement.
The company promised to publish the results from the trial in a peer-reviewed medical journal.
AstraZeneca in October enlisted Swiss contract manufacturer Lonza to produce the antibody drug in Portsmouth, New Hampshire, starting in the first half of 2021.
AZD7442 is being developed with support from the US government. AstraZeneca in March announced a deal with the US government to supply up to half a million doses of AZD7442. The company said on Tuesday it is now in talks with the US government regarding next steps on the deal.
FOLLOW US ON SOCIAL MEDIA AND SHARE WTX NEWS WITH YOUR FRIENDS AND FAMILY:
Facebook – Please like our page
Twitter – Twitter updates available in English and Arabic. Please follow us and we would love to hear from you
Instagram – Follow our pages in English and ArabicLeave a comment